Yongjia Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yongjia Yang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bingyin Jiang
Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing Laboratory of Biomedical Materials, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China
2 shared publications Haimei Zhu
Beijing Area Major Laboratory of Peptide and Small Molecular Drugs School of Pharmaceutical Sciences Capital Medical University Beijing 100069 China
1 shared publication- Hesong Wang
Beijing University of Chinese Medicine School of Life Sciences Beijing
1 shared publication - Jiang Lin
Department of Stomatology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
1 shared publication - Jiaxuan Zhao
Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Beijing Laboratory of Biomedical Materials, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China
1 shared publication Jilei Wang
Department of Stomatology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 31 December 2025
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (4) , 952-989
Dental plaque biofilm-targeting composite nanomaterials: advances and outlook
This review summarizes next-generation nanomaterials targeting dental plaque biofilms in periodontitis, highlighting nanomaterials that restore microbial balance and enable precision therapy.
- 31 December 2025
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (4) , 952-989
Dental plaque biofilm-targeting composite nanomaterials: advances and outlook
This review summarizes next-generation nanomaterials targeting dental plaque biofilms in periodontitis, highlighting nanomaterials that restore microbial balance and enable precision therapy.
- 24 July 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (27) , e02053
Polypeptide Single‐Chain Nanoparticle Derived Artificial Enzyme
Polyamino acids synthesized via ring‐opening polymerization (ROP) of N‐carboxyanhydride (NCA) monomers offer a scalable route to functional polypeptides, but the lack of sequence specificity limits their ability to fold and function like natural enzymes. Here, a series of artificial enzymes is developed based on single‐chain nanoparticles (SCNPs) formed through intramolecular folding of a triblock copolypeptide, polyethylene glycol‐b‐poly(L‐glutamic acid)‐b‐poly(oligo(ethylene glycol)‐L‐glutamate) (PEG113‐b‐PGlu112‐b‐P(Glu‐EG2)99). The central poly‐Glu block is intramolecularly cross‐linked via coordination with transition metal ions (Fe2+/Fe3+, Mn2+, Co2+, Cu2+/Zn2+), mimicking the natural folding of polypeptides into proteins. Co‐precipitation with ammonia water generates metal/alloy oxide nanoclusters within the cross‐linked polyGlu domain, providing a large surface‐to‐volume ratio. The metal oxide nanoclusters function as coenzymes. They not only facilitate a structural transition from α‐helices to β‐strands within the cross‐linked polyGlu domain but also demonstrate specific peroxidase (POD) or superoxide dismutase (SOD) activities, which are tailored to the specific metal species involved. The FeOx‐complexed artificial enzyme (Fe‐enzyme) is selected to exemplify its therapeutic effects of mitigating oxidative stress and inflammation in a rheumatoid arthritis mouse model. These artificial enzymes feature a soft, degradable polypeptide skeleton, tunable side‐chain functionalities, high enzyme‐like activity with minimal metal content (< 5 wt.%), and secondary structures similar to natural proteins.
- 24 July 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (27) , e02053
Polypeptide Single‐Chain Nanoparticle Derived Artificial Enzyme
Polyamino acids synthesized via ring‐opening polymerization (ROP) of N‐carboxyanhydride (NCA) monomers offer a scalable route to functional polypeptides, but the lack of sequence specificity limits their ability to fold and function like natural enzymes. Here, a series of artificial enzymes is developed based on single‐chain nanoparticles (SCNPs) formed through intramolecular folding of a triblock copolypeptide, polyethylene glycol‐b‐poly(L‐glutamic acid)‐b‐poly(oligo(ethylene glycol)‐L‐glutamate) (PEG113‐b‐PGlu112‐b‐P(Glu‐EG2)99). The central poly‐Glu block is intramolecularly cross‐linked via coordination with transition metal ions (Fe2+/Fe3+, Mn2+, Co2+, Cu2+/Zn2+), mimicking the natural folding of polypeptides into proteins. Co‐precipitation with ammonia water generates metal/alloy oxide nanoclusters within the cross‐linked polyGlu domain, providing a large surface‐to‐volume ratio. The metal oxide nanoclusters function as coenzymes. They not only facilitate a structural transition from α‐helices to β‐strands within the cross‐linked polyGlu domain but also demonstrate specific peroxidase (POD) or superoxide dismutase (SOD) activities, which are tailored to the specific metal species involved. The FeOx‐complexed artificial enzyme (Fe‐enzyme) is selected to exemplify its therapeutic effects of mitigating oxidative stress and inflammation in a rheumatoid arthritis mouse model. These artificial enzymes feature a soft, degradable polypeptide skeleton, tunable side‐chain functionalities, high enzyme‐like activity with minimal metal content (< 5 wt.%), and secondary structures similar to natural proteins.